Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01847092 · ClinicalTrials.gov registry record · Phase 2
A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
A Phase 2 study, sponsored by Ardelyx.
- Completed
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
NCT01847092 is a Phase 2 study that has completed, run by Ardelyx. The registered enrollment target is 154 participants.
The verdict
NCT01847092, a Phase 2 study, has completed, sponsored by Ardelyx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes.
Interventions
- DRUG Placebo
- DRUG AZD1722
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01847092
The ClinicalTrials.gov registry entry for NCT01847092 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardelyx, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01847092 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01847092 about?
NCT01847092 is a clinical study titled "A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria". The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes.
What is the current status of trial NCT01847092?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2013-05. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01847092?
The interventions under investigation include: Placebo (DRUG), AZD1722 (DRUG).
Who is sponsoring clinical trial NCT01847092?
This trial is sponsored by Ardelyx, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.